The exciting part is inMotion is only reaching 60M patients. The AGM preso states their 32,000+ US pharmacies has a pool of 230M patients. Plenty more to tap into.
They temper this announcement suggesting a $40M quarter in March shouldn't be expected due to the seasonal nature of programs in the US (winter).
March quarters have shown to be their lowest. If they can crank out $20M in March, then June should be $20M+ and they get $100M annual revenue.
The Twittersphere (when it loads - thanks for recent the AU/NZ throttling Elon!) is stating MedTech is the area to watch in 2023, plus copper and other commodities.
If for the $60M revenue in December, they can demonstrate it's achieved with less than $15M burn, the PFG debt looks to be payable without another CR.
I still believe there's another ~20% rise in share price to come in the short term. The price today is the same price after this announcement.
I hope the likes of Swinnerton, Xenos and Read stick around and don't sell out when there might be some movement.
Volume leads price and we're yet to see big days. Hopefully that changes in a few weeks.
The exciting part is inMotion is only reaching 60M patients. The...
Add to My Watchlist
What is My Watchlist?
